Ruthenium complexes with abiraterone acetate as antiproliferative agents.
J Inorg Biochem
; 262: 112754, 2024 Oct 05.
Article
in En
| MEDLINE
| ID: mdl-39383670
ABSTRACT
This study is dedicated to the development of multimodal anticancer agents. We have obtained ruthenium complexes conjugated with the steroid-type antitumor drug abiraterone acetate in order to take advantage of the dual antitumor properties of both ruthenium and abiraterone. The compounds exhibit good antiproliferative activity against cancer cells, with selectivity over primary fibroblasts. Real-time cell analysis revealed that compound dichlorido(η66-p-cymene)(abiraterone acetate)ruthenium(II) had pronounced antiproliferation activity compared to abiraterone acetate. Flow cytometric studies on the mechanism of cell death have revealed that the most active compound induces apoptosis more effectively than abiraterone acetate. Our findings demonstrate the potential of this novel dual-action compound as promising candidates for further development as anticancer agents.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
J Inorg Biochem
/
J. inorg. biochem
/
Journal of inorganic biochemistry
Year:
2024
Document type:
Article
Affiliation country:
RUSSIA
Country of publication:
United States